A phase I clinical trial of topical peptide p144 TGF-beta1 inhibitor in healthy volunteers

被引：0
|
作者：
Sabada, Belen [1 ]
Ruiz, Belen [2 ]
Ruiz, Juan
Insa, Raul [3 ]
机构：
[1] Univ Navarra Clin, Pamplona, Spain
[2] Hosp Univ Puerta de Hierro, Madrid, Spain
[3] ISDIN, Barcelona, Spain
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2009年 / 60卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB63 / AB63
页数：1
相关论文
共 50 条
  • [1] Nerve regeneration after local administration of the inhibitor peptide of the TGF-ß1 (P144®)
    Gomez R.
    Serra J.M.
    Bergera J.
    Ansó M.
    Gorría O.
    Qiu S.S.
    Aubá C.
    Hontanilla B.
    European Journal of Plastic Surgery, 2010, 33 (3) : 135 - 142
  • [2] P144 a Transforming Growth Factor Beta Inhibitor Peptide, Generates Antifibrogenic Effects in a Radiotherapy Induced Fibrosis Model
    Cruz-Morande, Sebastian
    Dotor, Javier
    San-Julian, Mikel
    CURRENT ONCOLOGY, 2022, 29 (04) : 2650 - 2661
  • [3] P144, an inhibitory peptide of the TGF-beta signaling pathway, inhibits growth and increases apoptosis in brain tumor cell lines
    Gallo, Gabriel
    Dotor, Javier
    Fan, Xing
    Borras-Cuesta, Francisco
    Castresana, Javier S.
    CANCER RESEARCH, 2011, 71
  • [4] TGF-β1 peptide-based inhibitor P144 ameliorates renal fibrosis after ischemia-reperfusion injury by modulating alternatively activated macrophages
    Li, Delun
    Zhang, Jian
    Yuan, Siyu
    Wang, Chao
    Chang, Jiakai
    Tong, Yan
    Liu, Ran
    Sang, Tian
    Li, Lili
    Li, Jijun
    Ouyang, Qing
    Chen, Xiangmei
    CELL PROLIFERATION, 2022, 55 (10)
  • [5] Topical application of p144, a peptide antagonist of transforming growth factor-beta 1, inhibits benign tumor formation and delays malignant conversion in skin chemical carcinogenesis
    Pons, Mar
    Dotor, Javier
    Quintanilla, Miguel
    Insa, Raul
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB137 - AB137
  • [6] P144, A TGF-β1 Antagonist Peptide, Synergizes with Sildenafil and Enhances Erectile Response via Amelioration of Cavernosal Fibrosis in Diabetic Rats
    Li, Wen Ji
    Wang, Hao
    Zhou, Juan
    Li, Bao
    Zhang, Jun
    Lu, Mujun
    Wang, Zhong
    JOURNAL OF SEXUAL MEDICINE, 2013, 10 (12): : 2942 - 2951
  • [7] Phase I clinical trial of cefditoren pivoxil (Me 1207): Pharmacokinetics in healthy volunteers
    Li, JT
    Hou, F
    Lu, H
    Li, TY
    Li, H
    DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 1997, 23 (5-6) : 145 - 150
  • [8] Safety Evaluation of Topical Application of Nano-Liposomal Form of Amphotericin B (SinaAmpholeish) on Healthy Volunteers: Phase I Clinical Trial
    Eskandari, Seyed Ebrahim
    Firooz, Alireza
    Nassiri-Kashani, Mansour
    Jaafari, Mahmoud Reza
    Javadi, Amir
    Miramin Mohammadi, Akram
    Khamesipour, Ali
    IRANIAN JOURNAL OF PARASITOLOGY, 2019, 14 (02) : 197 - 203
  • [9] Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial
    Citron, Diane M.
    Tyrrell, Kerin L.
    Dale, Suzanne E.
    Chesnel, Laurent
    Goldstein, Ellie J. C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (04) : 2069 - 2074
  • [10] P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines
    Gallo-Oller, Gabriel
    Vollmann-Zwerenz, Arabel
    Melendez, Barbara
    Rey, Juan A.
    Hau, Peter
    Dotor, Javier
    Castresana, Javier S.
    CANCER LETTERS, 2016, 381 (01) : 67 - 75
12345